Literature DB >> 15118829

[Hepatitis as a travel disease].

J Hadem1, H Wedemeyer, M P Manns.   

Abstract

Every year over 50 million people travel from industrialized countries to areas with high prevalence of oral-fecal and sexually transmissible forms of viral hepatitis. The risk of infection with hepatitis A is associated with the standard of living, the length of stay, and the area of destination. Acute hepatitis E is predominantly transmitted in India and other Asian countries. The main risk factors for the acquisition of hepatitis B are sexual promiscuity and unprotected sexual intercourse. This report provides detailed information on the risk of hepatitis in travelers, available vaccination schedules, clinical and laboratory diagnostic features, and necessary therapeutic aspects in cases of ongoing acute viral hepatitis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15118829     DOI: 10.1007/s00108-004-1197-4

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  38 in total

Review 1.  Cytokine-mediated control of viral infections.

Authors:  L G Guidotti; F V Chisari
Journal:  Virology       Date:  2000-08-01       Impact factor: 3.616

2.  Protecting travellers from hepatitis A.

Authors:  G Webster; E Barnes; G Dusheiko; I Franklin
Journal:  BMJ       Date:  2001-05-19

Review 3.  [Travel and hepatitis].

Authors:  M P Manns; A Schüler
Journal:  Internist (Berl)       Date:  1999-11       Impact factor: 0.743

Review 4.  Hepatitis E: an overview and recent advances in clinical and laboratory research.

Authors:  R Aggarwal; K Krawczynski
Journal:  J Gastroenterol Hepatol       Date:  2000-01       Impact factor: 4.029

5.  Empiric immunization versus serologic screening: developing a cost-effective strategy for the use of hepatitis A immunization in travelers.

Authors:  Joel T Fishbain; Robert E Eckart; Kyle C Harner; Duane R Hospenthal
Journal:  J Travel Med       Date:  2002 Mar-Apr       Impact factor: 8.490

6.  Immunogenicity of an accelerated vaccination regime with a combined hepatitis a/b vaccine in patients with chronic hepatitis C.

Authors:  B Kallinowski; W Jilg; L Buchholz; W Stremmel; S Engler
Journal:  Z Gastroenterol       Date:  2003-10       Impact factor: 2.000

7.  Knowledge, attitudes and practices in travel-related infectious diseases: the European airport survey.

Authors:  Koen Van Herck; Pierre Van Damme; Francesco Castelli; Jane Zuckerman; Hans Nothdurft; Atti-La Dahlgren; Sandra Gisler; Robert Steffen; Panagiotis Gargalianos; Rogelio Lopéz-Vélez; David Overbosch; Eric Caumes; Eric Walker
Journal:  J Travel Med       Date:  2004 Jan-Feb       Impact factor: 8.490

8.  Immunogenicity of combined hepatitis A and B vaccine in elderly persons.

Authors:  Bernd Wolters; Ulrich Junge; Stefan Dziuba; Michael Roggendorf
Journal:  Vaccine       Date:  2003-09-08       Impact factor: 3.641

9.  Hepatitis E: evidence for person-to-person transmission and inability of low dose immune serum globulin from an Indian source to prevent it.

Authors:  M S Khuroo; M Y Dar
Journal:  Indian J Gastroenterol       Date:  1992-07

10.  The diverse patterns of hepatitis A epidemiology in the United States-implications for vaccination strategies.

Authors:  B P Bell; C N Shapiro; M J Alter; L A Moyer; F N Judson; K Mottram; M Fleenor; P L Ryder; H S Margolis
Journal:  J Infect Dis       Date:  1998-12       Impact factor: 5.226

View more
  2 in total

1.  [Prevention of virus hepatitis A to E].

Authors:  M Cornberg; M P Manns
Journal:  Internist (Berl)       Date:  2011-03       Impact factor: 0.743

2.  [Diagnostics and therapy of hepatitis].

Authors:  C P Strassburg; M Cornberg
Journal:  Internist (Berl)       Date:  2009-12       Impact factor: 0.743

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.